Tag: obesity

PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the “Board”) has approved a deferral of the previously announced record date of May 2, 2025 for the Company’s previously announced dividend of Scilex preferred stock (the “Dividend”) to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be such later date to be determined in the sole discretion of the Board (such later record date as so determined by the Board, the “New Record Date”). The Board retains the right to continue to change any New Record Date (and therefore any related payment date for the Dividend) and the ability to revoke the Dividend.

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic^® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.